Relationships Between Plasma IGF-I and Markers for Atherosclerotic Plaque Stability and Platelet Function in Patients with Type 1 Diabetes
Presentation Number: SUN 458
Date of Presentation: April 2nd, 2017
Jeanette Wahlberg*1, Andreas Eriksson2, Bertil Ekman1 and Per Whiss2
1Linköping University, Linköping, Sweden, 2Division of Drug Research and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden
Abstract: Atherothrombotic complications are common causes of morbidity and mortality in patients with diabetes. The stability of the atherosclerotic plaque is influenced by various factors such as matrix metalloproteinases (MMPs), tissue inhibitors of MMPs (TIMPs) and adiponectin. Moreover, in type 1 diabetes patients plasma IGF-I has been found to be decreased, especially in patients with low endogenous insulin secretion (1). Low IGF-I levels found in type 1 diabetes has been partly reversed via intraportal insulin treatment or via recombinant IGF-I replacement therapy. The aim of this study was to elucidate relationships between circulating IGF-I levels and different markers for atherosclerotic plaque stability and platelet/coagulation function in patients with type 1 diabetes. Thirty-four patients with childhood onset of type 1 diabetes 27 ±4 years of age (range 20–35 years), and disease duration 21 ±5 years (range10–31 years) were investigated. S-IGF-I, S-HbA1c, P-Selectin (platelet aggregation), P-MMP-9 (collagen break down), P-TIMP-1 (inhibition of MMP), P-Fibrinogen (blood clotting) and P-Adiponectin (plaque stabilization) were measured.
S-IGF-I was negatively correlated with age r= -0.36, p=0.007, while no significant correlations were found with S-HbA1c. A strong negative correlation between S-IGF-I and P-Selectin r= -0.53, p=0.001 was found. S-IGF-I was also negatively correlated with P-TIMP-1, r= -0.44, p=0.009, and positively correlated with P-Fibrinogen, r= 0.38, p=0.035. No significant correlations were found between S-IGF-I and P-Adiponectin, P-MMP-9 or MMP/ TIMP-1. Low plasma IGF-I levels was associated with platelet hyperreactivity and an imbalance in plaque stability markers in young adults with type 1 diabetes. Further investigations are necessary to determine whether a normalization of IGF-I levels provide benefits to patients with type 1 diabetes.
Nothing to Disclose: JW, AE, BE, PW